A South Korean investment firm starts first US biotech fund
Mirae Asset Capital Life Science, a new venture capital fund, launched on Thursday, joining several other new firms that have recently emerged with plans to invest in drug startups. The fund is a spinout of Mirae Asset Financial Group, a…
Kyverna sets plans for IPO in test of biotech enthusiasm
Dive Brief: Kyverna Therapeutics on Tuesday revealed plans to go public, testing the waters in a biotechnology market that hasn’t fully recovered from a downturn that started in 2021. The offering would fund Kyverna’s cell therapy work, which is led…
Comanche Biopharma raises $75M to fund preeclampsia drug testing
Dive Brief: Massachusetts-based startup Comanche BioPharma has raised $75 million in new venture funding to advance an experimental treatment targeting a cause of the pregnancy-related condition preeclampsia. Preeclampsia involves sudden blood pressure spikes that can lead to serious complications for…
FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia
The Food and Drug Administration on Tuesday approved Vertex Pharmaceuticals’ CRISPR-based medicine Casgevy for the inherited blood condition beta thalassemia, expanding its use six weeks after issuing a landmark clearance in sickle cell disease. The agency’s decision makes Casgevy, which in…
The biopharma industry outlook on 2024: Guarded optimism for a rebound
Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley…
Newly optimistic, biotech investors weigh lessons of sector’s downturn
The J.P. Morgan Healthcare Conference, a yearly temperature taker for the biotechnology industry, had a different feel in 2024. For the first time in awhile, young drugmakers and their backers were optimistic the sector’s downturn might finally be over. An…
EU regulators to consult advisers in review of Eisai Alzheimer’s drug
European regulators will seek outside advice before making a decision on approval of Eisai and Biogen’s Leqembi medicine for Alzheimer’s disease. The Committee for Medicinal Products for Human Use opted to convene a meeting of a scientific advisory group, which…
FDA says no ‘clear relationship’ between GLP-1 drugs and suicide risk
Dive Brief: The use of GLP-1-based drugs to treat obesity and diabetes has no “clear relationship” with the risk of suicidal thoughts or actions, the Food and Drug Administration said Thursday after completing a review of reports in its adverse…
Backed by billionaires, a new biomedical institute tests an unorthodox approach
A group of high-profile scientists and billionaire financiers are building a new biomedical research institute that they claim will offer a new model for studying disease biology and developing new drugs. Arena BioWorks, which publicly launched Friday, is led by…
Recursion’s Chris Gibson on AI in biotech and ‘virtuous cycles’
Chris Gibson, the CEO of Recursion Pharmaceuticals, thinks the future of drug discovery lies within a ChatGPT-like interface. At a J.P. Morgan Healthcare Conference reception co-hosted with Nvidia, the tech giant now making inroads with biotechnology investment, the Salt Lake…
Venture funding, dealmaking slowed in biotech last year: Pitchbook
Dive Brief: The number and amount of biotechnology financings dipped in 2023, with venture firms investing 25% fewer dollars in companies compared to the year prior, according to new quarterly data released Thursday from Pitchbook and the National Venture Capital…
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
The mood shifts on the third day of the J.P. Morgan Healthcare Conference. Deals have been announced and news peters out. The most closely-watched companies have already presented. Investors and executives are worn down from two frenzied days of meetings….
5 questions facing pharma in 2024
The arrival of powerful new drugs for obesity has reshaped the pharmaceutical industry, transforming Eli Lilly and Novo Nordisk into the sector’s most valuable companies and sending others scrambling to catch up. Analysts predict that so-called GLP-1 drugs like Lilly’s…
GSK to buy asthma drug startup Aiolos for $1B
Over the span of five months, biotechnology startup Aiolos Bio launched, raised initial funding from venture investors and negotiated a $1 billion buyout by GSK. The acquisition, announced by GSK on Tuesday, marks a rapid return on investment for Aiolos’…
JPM24: Pfizer’s tough sell, the next Karuna and building a biotech platform
Biotechnology’s embrace of artificial intelligence was never more literal than Tuesday at the J.P. Morgan Healthcare Conference, when AI drug discovery specialist Recursion handed out umbrellas in front the Westin St. Francis to combat the inevitable San Francisco rain. AI,…
FDA authorizes Florida to import drugs from Canada
For the first time, the Food and Drug Administration has authorized a U.S. state to import prescription drugs from Canada, granting Florida preliminary clearance to bulk purchase medicines from wholesalers there. The decision is a major policy shift for the…
An unusual drugmaker raises north of $100M for ecstasy-based PTSD therapy
A California-based company has raised tens of millions of dollars to support its mission of bringing an ecstasy-based therapy to patients with post-traumatic stress disorder. MAPS Public Benefit Corp. formed a decade ago as a subsidiary of the Multidisciplinary Association…
Allogene to shift strategy in bid to reposition CAR-T
Dive Brief: Allogene Therapeutics, a leading developer of “off-the-shelf” cell therapies for cancer, will deprioritize two of its most advanced clinical trials as part of a new plan to improve on other cell-based medicines. The biotechnology company is dialing back…
Intellia to lay off staff, cut some early research
CRISPR specialist Intellia Therapeutics on Thursday said it will lay off about 15% of its workforce as it pauses some early-stage research. The cuts come a little over three months after Intellia, one of the first companies founded to turn…
Goldman Sachs gets into biotech investing with new venture fund
Dive Brief: Goldman Sachs Asset Management has wrapped up fundraising for the first fund in its Life Sciences investment venture, securing $650 million in equity commitments. The fundraising exceeded the firm’s target and ranks as one of the largest-ever rounds…
Pfizer wins Canadian OK for hemophilia treatment, its first gene therapy
Dive Brief: Canada’s health regulators have approved Pfizer’s gene therapy for hemophilia B, the company said Wednesday, making it the first time the drugmaker has received regulatory clearance for such a genetic medicine. The gene therapy, which Pfizer licensed nine…
FDA ends busy year with three drug rejections
The Food and Drug Administration closed out 2023 with rejections of three drugmaker applications for first approval or expanded use, handing Amgen, Zealand Pharma and Merck & Co. complete response letters for medicines to treat cancer, low blood sugar and…
Novartis deepens ties with Voyager via $100M gene therapy deal
Dive Brief: Swiss pharmaceutical company Novartis has formed a new collaboration with partner Voyager Therapeutics, agreeing Tuesday to license one experimental gene therapy and the tools to develop another. Novartis will pay the biotechnology company $100 million in cash upfront,…
10 clinical trials to watch in the first half of 2024
A non-addictive pain pill faces its definitive test, while study results in ALS, a rare heart disease and lung cancer could have far-reaching implications.
Argenx autoimmune drug study fails in blow to expansion hopes
Dive Brief: Argenx lost a quarter of its value Wednesday after reporting the second research setback in two months for its bid to expand use of its only approved drug. The latest study, called Address, showed no significant benefit for…
Sanofi scraps a top ADC prospect after study setback
Dive Brief: Sanofi will stop developing one of its top cancer drug prospects after the experimental treatment fell short in a late-stage study in advanced lung cancer, the company said Thursday. Trial monitors found the drug, dubbed tusamitamab ravtansine, missed…
J&J bets bigger on MeiraGTx’s eye gene therapy
Dive Brief: Gene therapy developer MeiraGTx is selling its remaining financial interest in an eye-disease treatment partnered with Johnson & Johnson, announcing Thursday it is receiving $65 million up front and potentially another $65 million next year in exchange for…
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug
Dive Brief: The Food and Drug Administration on Thursday approved a new medicine for a form of the rare disease transthyretin amyloidosis, clearing AstraZeneca and Ionis Pharmaceuticals’ Wainua for adults with the condition. The drug, formerly known as eplontersen, has…
Bristol Myers to acquire brain drug developer Karuna for $14B
Bristol Myers Squibb has agreed to acquire Karuna Therapeutics for $14 billion, betting that the biotechnology company’s experimental schizophrenia drug will become a top-selling medicine. Per deal terms announced Friday, Bristol Myers will pay $330 a share for Karuna, a…
Sarepta tests FDA flexibility with bid to expand Duchenne gene therapy’s approval
Sarepta Therapeutics has asked the Food and Drug Administration to expand approval of its gene therapy for Duchenne muscular dystrophy, banking on the regulator’s flexibility in reviewing conflicting clinical trial data. The biotechnology company is requesting the FDA clear its…
Clene says its ALS drug data is not yet enough for FDA
Dive Brief: Clene Nanomedicine on Thursday said the Food and Drug Administration doesn’t believe the company has gathered enough evidence to support an accelerated approval of its experimental drug for ALS, or amytrophic lateral sclerosis. A solution of gold nanoparticles,…
BioMarin strikes deal with Elliott, agrees to review business
Dive Brief: Weeks after installing a new CEO, BioMarin Pharmaceutical is overhauling oversight of the company at the board level. Facing pressure from activist investor Elliott Investment Management, BioMarin’s board named three new independent directors and set up a Strategic…
GSK adds to ADC dealmaking with second Chinese biotech pact
Dive Brief: GSK is deepening its investment in cancer treatments called antibody-drug conjugates, announcing Wednesday plans to pay $185 million to China-based Hansoh Pharma to license an experimental drug that has shown promise in lung, bone and soft tissue cancers….
As ALS research booms, one treatment center finds itself in the spotlight
Merit Cudkowicz has spent her career treating some of the most unforgiving illnesses. She’s watched Alzheimer’s disease steal memories and Huntington’s disease take control of muscles. But the cruelest may be ALS, or amyotrophic lateral sclerosis, a rare, fatal condition…
Investors still aren’t sold on UniQure’s gene therapy for Huntington’s
Dive Brief: Shares of UniQure dipped more than 10% Tuesday morning after the biotechnology company released more data from a small study testing an experimental gene therapy for Huntington’s disease. The new results include up to 30 months of follow-up…
Illumina to part with Grail, ending battle with regulators
Dive Brief: DNA sequencing company Illumina said Sunday it will divest Grail, the liquid biopsy maker it fought to hang onto after purchasing the business for $8 billion more than two years ago over the objections of U.S. and European…
Foundation behind Novo Nordisk to invest $260M in vaccine R&D
Dive Brief: The Novo Nordisk Foundation, which owns a controlling stake in drugmaker Novo Nordisk, said Monday it will invest 1.8 billion Danish kroner, or about $260 million, to fund development of new vaccines for respiratory diseases. The new initiative…
Pivotal Life Sciences reloads with $389M, hunting for deals in a downturn
Dive Brief: Venture capital group Pivotal Life Sciences has raised its second fund, securing $389 million to invest in young drugmakers, the firm announced Monday. Pivotal, which has offices in San Francisco and Cambridge, Massachusetts, previously raised $300 million for…
Apellis eye drug likely to be rejected in Europe, company says
European drug reviewers appear likely to recommend against clearing a new medicine from Apellis Pharmaceuticals in another stumble for a first-of-its-kind treatment the Food and Drug Administration approved earlier this year. In a statement Thursday, Apellis said it’s been informed…
Editas cashes in on CRISPR patent with Vertex deal
Dive Brief: Days after winning U.S. approval of the first CRISPR gene-editing medicine, Vertex Pharmaceuticals is clearing up potential intellectual property questions about the sickle cell disease therapy by signing a deal with Editas Medicine. In return for a non-exclusive…
New Moderna cancer vaccine data spurs share rally
Dive Brief: An experimental cancer vaccine from Moderna and Merck & Co. continued to show promise in treating melanoma, with newly released evidence showing that a combination of the shot and the immunotherapy Keytruda kept more people alive and disease-free…
European regulators push Biogen, CRISPR drugs toward approval
The committee that recommends whether drugs should be approved in Europe has thrown its support behind the first medicine based on CRISPR gene editing technology, issuing on Friday a positive opinion of the treatment, known as Casgvey. The committee’s decision…
FDA widens use of cancer drug Merck acquired for $1B
Dive Brief: The Food and Drug Administration on Thursday broadened use of a drug Merck & Co. acquired in a $1 billion buyout four years ago, clearing Welireg for use in people whose kidney tumors have progressed following treatment with two…
Amgen finds a new top scientist in Novartis veteran Bradner
Amgen has a new top scientist, announcing Thursday the appointment of Novartis veteran and prolific biotechnology startup founder Jay Bradner alongside another change to its leadership team. Bradner led the Novartis Institutes of BioMedical Research — the Swiss pharmaceutical giant’s…
Vir to lay off staff, cut costs amid setbacks building on COVID success
Dive Brief: Vir Biotechnology on Thursday announced a restructuring that will result in a 12% reduction in its workforce as well as the closure of some of its research and development facilities. The company said the restructuring will help prioritize…
Pfizer to deepen cost cuts as latest sales forecasts miss expectations
Pfizer on Wednesday upped the target for its cost-cutting program, revealing the additional spending cuts alongside a sales forecast for 2024 that disappointed Wall Street analysts and sent shares down to their lowest levels in more than a decade. Pfizer…
Supreme Court to rule on abortion pill access
The U.S. Supreme Court announced Wednesday it will review a lower-court ruling that would restrict access to the widely used abortion pill mifepristone, bringing a high-profile battle over reproductive rights back to the same court that overturned Roe v. Wade last…
AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B
Dive Brief: AstraZeneca on Tuesday reached a deal to acquire vaccine developer Icosavax in a deal worth up to $1.1 billion. Per deal terms, AstraZeneca will acquire Icosavax’s shares at $15 apiece, and could add another $5 per share to the…
FTC, in unusual move, leads Sanofi to terminate a drug research deal
Dive Brief: Sanofi terminated a licensing deal with biotechnology company Maze Therapeutics Monday after the Federal Trade Commission filed a lawsuit alleging that the collaboration was designed to extend the French drugmaker’s monopoly in treating a rare disorder known as Pompe…
Tome Biosciences debuts with $213M and a new way to edit the genome
Dive Brief: Biotechnology startup Tome Biosciences emerged from stealth on Tuesday with $213 million in venture funding to develop a new gene editing technology it believes can overcome some of the limitations of existing methods. Called “programmable genomic integration,” or…
ASH23: Pharma branding, Editas’ high bar and clinical trial diversity
SAN DIEGO — At the American Society of Hematology’s annual meeting, pharmaceutical branding is inescapable. Johnson & Johnson’s and GSK’s new logos are splashed across the side of phone charging stations. Sanofi, among others, let attendees know via hand sanitizer…
Life sciences leaders invest in process mining to accelerate digital transformation
The life sciences industry is evolving rapidly in response to macroeconomic shifts, regulatory changes, cost pressures, large data volumes and increasing competition. Leading organizations are investing in process mining technology to optimize their business processes, according to Everest Research Group’s…
‘No tolerance for failure’: An oral history of the first CRISPR medicine
The last line of this century’s most important biomedical research paper contained a hint of the scientific revolution to come. An ancient bacterial defense system, the researchers wrote in 2012, could be adapted to offer “considerable potential for gene targeting…
ASH23: CAR-T for autoimmune disease, real-world questions and sickle cell’s social media mentions
SAN DIEGO —The 65th annual meeting of the American Society of Hematology got a dramatic introduction. On Friday, as researchers and doctors arrived here, the Food and Drug Administration approved two gene therapies for sickle cell disease, an inherited condition…
Bluebird gene therapy, now approved for sickle cell, shows durable benefit in study update
The vast majority of the people who received Bluebird bio’s newly approved sickle cell disease medicine in a clinical trial remained free of the frequent pain crises typical of their condition, some for as long as five years, new study…
Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs
Dive Brief: Spyre Therapeutics, a biotechnology spinout working on antibody drugs for diseases of the gut, announced Friday a $180 million fundraising from a group of blue-chip investors. In June, Spyre launched as a publicly traded company when it entered…
Pricey new gene therapies for sickle cell pose access test
The first gene therapies for sickle cell disease may treat the inherited blood condition for many years, if not a lifetime. They will also cost several million dollars. On Friday, Vertex Pharmaceuticals set the list price of Casgevy, the first…
Radiopharma startup Artbio raises $90M in sign of field’s momentum
Dive Brief: Biotechnology startup Artbio said Thursday it raised $90 million in a Series A financing that highlighted investors’ appetite for an emerging class of cancer medicines known as radiopharmaceuticals. Third Rock Ventures and an undisclosed healthcare fund led the…
Biden administration goes after drug patents in bid to lower prices
The White House on Thursday took steps to pressure pharmaceutical companies to lower the price of drugs developed with federal funding, backing a plan that would enable the government to sidestep patent protections for those medicines. New draft guidelines published…
Biotech venture firms continue ‘recalibration’ in third quarter, Pitchbook report finds
Dive Brief: Venture capital activity in biotechnology is undergoing a “recalibration towards pre-pandemic investment norms,” according to a new quarterly report from Pitchbook that tracks global funding and dealmaking in the sector. Pitchbook projects there will be about 840 venture…
AbbVie to buy Cerevel in $8.7B bet on brain drugs
AbbVie is restocking its drug pipeline in a big way, announcing Wednesday an $8.7 billion deal to buy neuroscience-focused Cerevel Therapeutics, just days after agreeing to a similar sized acquisition of the cancer biotechnology company ImmunoGen. Per the deal, AbbVie…
Pfizer, after delay, completes enrollment in Lyme vaccine trial
Dive Brief: Pfizer and partner Valneva announced Monday that they have finished enrolling participants in a Phase 3 trial evaluating their experimental vaccine for Lyme disease. The announcement ends a lengthy delay that began in February, when the two companies…
BIO names longtime Amicus head John Crowley as its new CEO
The Biotech Innovation Organization on Tuesday named Amicus Therapeutics co-founder and longtime leader John Crowley as its new CEO, taking over a spot interim chief Rachel King has held for the past 14 months. BIO’s decision to name Crowley, who…
EyePoint sees stock surge on AMD drug trial data
Shares in EyePoint Pharmaceuticals more than tripled Monday morning after the Massachusetts-based biotechnology company announced summary results from a mid-stage study of an experimental eye disease drug it’s developing. EyePoint’s medicine, called vorolanib, matched the performance of Regeneron’s top-selling drug…
Lilly cancer drug cleared by FDA for expanded leukemia, lymphoma use
Dive Brief: The Food and Drug Administration granted conditional approval to Eli Lilly’s oral cancer drug Jaypirca in two types of blood cancer, expanding its use from a rare type of lymphoma to people with leukemia and lymphoma patients who…
Revolutionizing clinical trials: Unlocking peak efficiency with total laboratory automation in bioanalysis
With clinical trials becoming more complex, finding ways to streamline and automate laboratory processes is vital when analyzing bioanalytical samples. As the chief scientific officer of large-molecule bioanalysis, Dr. Tom Zhang leverages his expertise to promote ever-evolving automation technologies. He…
FDA names chief scientist Bumpus as Woodcock’s successor
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday. Among Bumpus’ priorities when she…
CRO disputes Acelyrin’s implication of trial misconduct
Dive Brief: A contract research organization working for biotechnology company Acelyrin is disputing suggestions that it may be responsible for the failure of a high-profile study released in September. On Monday, Acelyrin said it began implementing extra quality control measures…
Pfizer plans for oral obesity drug hit new setback
Dive Brief: Pfizer will not advance a twice-daily dose of an experimental obesity drug into further testing after results from a mid-stage study showed high rates of gastrointestinal side effects and participant dropout. Treatment did lead to significant weight loss…
Concentra, on the hunt for deals, bids for LianBio
Dive Brief: Concentra Biosciences has made an unsolicited bid to acquire all outstanding shares of LianBio, a biotechnology company focused on bringing medicines to China and other Asian markets. Concentra, which is controlled by Tang Capital, is offering $4.30 per…
European regulators want to know more about the risks of GLP-1 drugs
Europe’s drug regulator has more questions about the safety and potential risks of a new, widely popular class of medicines. Known as GLP-1 agonists, the class includes Novo Nordisk’s Ozempic, Wegovy, Rybelsus and Saxenda, as well as Eli Lilly’s Trulicity….
Flagship outlines plans to raise $3B for new fund
Flagship Pioneering is looking to raise $3 billion for its eighth venture fund, a sign the high-profile company creator continues to see investor interest in the biotechnology sector despite a turbulent market. The plans were outlined in a securities document…
AbbVie joins ADC dealmaking with $10B ImmunoGen buyout
AbbVie is expanding its investment in targeted cancer medicines, announcing Thursday a $10.1 billion deal to acquire ImmunoGen, a pioneer in the field of so-called antibody-drug conjugates, and its newly approved ovarian cancer treatment Elahere. The transaction is this year’s…
Gilead to lay off staff at cell therapy unit Kite
Dive Brief: Gilead Sciences is laying off about 7% of employees at cell therapy unit Kite Pharma in a restructuring it said is meant to better align the division’s organization with areas of future growth. About 90 new positions will…
Cigna, Humana in talks to merge: WSJ
Dive Brief: Cigna and Humana are in talks to merge, according to the Wall Street Journal. The two health insurers are discussing a stock-and-cash deal that could be finalized by the end of this year, WSJ reported on Wednesday, citing sources…
FDA investigating cancer risk linked to CAR-T cell therapy
The Food and Drug Adminsitration is investigating whether CAR-T cell therapies like Novartis’ Kymriah or Gilead’s Yescarta are linked to the risk of new blood cancers after receiving reports of so-called T cell malignancies in people who have received the…
Bristol Myers pours $100M into RNA drugs for cardiovascular diseases
Bristol Myers Squibb has agreed to spend at least $100 million to expand a partnership aimed at creating RNA-based medicines for cardiovascular diseases. The deal, announced Tuesday, shows Bristol Myers is willing to bet more on drugmaking technology developed by…
GSK cancer drug Blenrep gets surprise trial win
Dive Brief: GSK on Monday said its drug Blenrep outperformed Johnson & Johnson’s Darzalex in a clinical trial of people with the blood cancer multiple myeloma, potentially cracking open the door to Blenrep’s relaunch one year after the company pulled…
Novo to expand French plant in GLP-1 production push
Dive Brief: Novo Nordisk on Thursday said it will invest more than 16 billion Danish kroner, or about $2.3 billion, to expand a drug production site in Chartres, France, as it works to keep up with demand for medicines like…
AstraZeneca creates digital health unit, with big-name partnerships already in place
Dive Brief: AstraZeneca’s new health-tech business, Evinova, launched Monday, with several big-name partnerships already in place and a goal to “better meet the needs of healthcare professionals, regulators and patients.” Evinova’s main focus will be helping to optimize clinical trials…
Bristol Myers faces FDA delay on cancer cell therapy decision
Dive Brief: The Food and Drug Administration plans to hold an advisory panel review of Bristol Myers Squibb and 2seventy bio’s application for an expanded approval of their multiple myeloma cancer therapy Abecma, the partner companies said Monday. As a…
Bayer ends large blood thinner trial for ‘inferior efficacy’
Bayer is stopping a large clinical trial testing its experimental blood thinner asundexian in people with irregular heartbeats because it didn’t work as well as Bristol Myers Squibb’s Eliquis, the company said Monday. Shares in the German drugmaker fell by…
Medtronic CEO downplays impact of obesity drugs on procedures, devices
By the numbers FY2024 Q2 revenue: $7.98 billion 5.3% year-over-year growth Medical Surgical revenue: $2.14 billion 7% year-over-year growth Diabetes revenue: $610 million 9.7% year-over-year growth Medtronic CEO Geoff Martha on Tuesday became the latest medtech executive…
Roche’s Genentech partners with Nvidia in AI drug deal
Roche’s Genentech unit is partnering with computing giant Nvidia in a multiyear deal that highlights the pharmaceutical industry’s growing hopes of using artificial intelligence to speed up the process of designing and developing new drugs. By collaborating with Nvidia, Genentech…
Quotient emerges from Flagship with plan to explore somatic mutations
Dive Brief: Quotient Therapeutics, a biotechnology company focused on studying the role of somatic mutations in disease, emerged from stealth Tuesday with $50 million from Flagship Pioneering. The company aims to use single-cell gene sequencing and computational techniques to parse…
Merck to buy private biotech Caraway in neuroscience deal
Dive Brief: Merck & Co. will pay as much as $610 million to acquire private biotechnology company Caraway Therapeutics in a deal that expands Merck’s research presence in neurodegenerative disease. Announced Tuesday, the deal involves an undisclosed upfront payment along…
Freeline, after cuts, agrees to take-private deal with Syncona
Freeline Therapeutics, a U.K.-headquartered developer of gene therapies, has agreed to be taken private in a deal with British investment firm Syncona, the companies announced Tuesday. Syncona, which already owned more than half of Freeline, will pay $6.50 per American…
Flagship-backed microbiome biotech Evelo to shut down
Evelo Biosciences, a biotechnology company launched by Flagship Pioneering to develop microbiome drugs, is shutting down, according to a regulatory filing. The move follows setbacks for the company, which was testing its lead drug candidate for inflammatory skin conditions. That…
Are cake Delta 8 disposables safe?
cake Delta 8 disposables safe Delta 8 is a cannabinoid that produces intoxicating effects when vaped. It’s an analog of Delta 9 THC, the primary psychoactive compound in cannabis plants. Before buying a Cake Delta 8 cartridge, make sure it’s…